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The International Agency for Research on
Cancer (IARC) Monographs Programme
identifies chemicals, drugs, mixtures,
occupational exposures, lifestyles and per-
sonal habits, and physical and biological
agents that cause cancer in humans and
has evaluated about 1000 agents since
1971. Monographs are written by ad hoc
Working Groups (WGs) of international
scientific experts over a period of about
12 months ending in an eight-day
meeting. The WG evaluates all of the
publicly available scientific information on
each substance and, through a transparent
and rigorous process,1 decides on the
degree to which the scientific evidence
supports that substance’s potential to
cause or not cause cancer in humans.
For Monograph 112,2 17 expert scien-
tists evaluated the carcinogenic hazard for
four insecticides and the herbicide glypho-
sate.3 The WG concluded that the data
for glyphosate meet the criteria for classi-
fication as a probable human carcinogen.
The European Food Safety Authority
(EFSA) is the primary agency of the
European Union for risk assessments
regarding food safety. In October 2015,
EFSA reported4 on their evaluation of the
Renewal Assessment Report5 (RAR) for
glyphosate that was prepared by the
Rapporteur Member State, the German
Federal Institute for Risk Assessment
(BfR). EFSA concluded that ‘glyphosate is
unlikely to pose a carcinogenic hazard to
humans and the evidence does not
support classification with regard to its
carcinogenic potential’. Addendum 1 (the
BfR Addendum) of the RAR5 discusses the
scientific rationale for differing from the
IARC WG conclusion.
Serious flaws in the scientific evaluation
in the RAR incorrectly characterise the
potential for a carcinogenic hazard from
exposure to glyphosate. Since the RAR is
the basis for the European Food Safety
Agency (EFSA) conclusion,4 it is critical
that these shortcomings are corrected.
THE HUMAN EVIDENCE
EFSA concluded ‘that there is very limited
evidence for an association between
glyphosate-based formulations and
non-Hodgkin lymphoma (NHL), overall
inconclusive for a causal or clear associa-
tive relationship between glyphosate and
cancer in human studies’. The BfR
Addendum (p. ii) to the EFSA report
explains that ‘no consistent positive asso-
ciation was observed’ and ‘the most
powerful study showed no effect’. The
IARC WG concluded there is limited evi-
dence of carcinogenicity in humans which
means “A positive association has been
observed between exposure to the agent
and cancer for which a causal interpret-
ation is considered by the Working Group
to be credible, but chance, bias or con-
founding could not be ruled out with rea-
sonable confidence.”1
The finding of limited evidence by the
IARC WG was for NHL, based on high-
quality case–control studies, which are
particularly valuable for determining the
carcinogenicity of an agent because their
design facilitates exposure assessment and
reduces the potential for certain biases.
The Agricultural Health Study6 (AHS)
was the only cohort study available pro-
viding information on the carcinogenicity
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of glyphosate. The study had a null
finding for NHL (RR 1.1, 0.7–1.9) with
no apparent exposure–response relation-
ship in the results. Despite potential
advantages of cohort versus case–control
studies, the AHS had only 92 NHL cases
in the unadjusted analysis as compared to
650 cases in a pooled case–control ana-
lysis from the USA.7 In addition, the
median follow-up time in the AHS was
6.7 years, which is unlikely to be long
enough to account for cancer latency.8
The RAR classified all of the case–
control studies as ‘not reliable,’ because,
for example, information on glyphosate
exposure, smoking status and/or previous
diseases had not been assessed. In most
cases, this is contrary to what is actually
described in the publications.
Well-designed case–control studies are
recognised as strong evidence and rou-
tinely relied on for hazard evaluations.9 10
The IARC WG carefully and thoroughly
evaluated all available epidemiology data,
considering the strengths and weaknesses
of each study. This is key to determining
that the positive associations seen in the
case–control studies are a reliable indica-
tion of an association and not simply due
to chance or methodological flaws. To
provide a reasonable interpretation of the
findings, an evaluation needs to properly
weight studies according to quality rather
than simply count the number of positives
and negatives. The two meta-analyses
cited in the IARC Monograph11 are excel-
lent examples of objective evaluations and
show a consistent positive association
between glyphosate and NHL.
The final conclusion5 (Addendum 1,
p.21) that “there was no unequivocal evi-
dence for a clear and strong association of
NHL with glyphosate” is misleading.
IARC, like many other groups, uses three
levels of evidence for human cancer data.1
Sufficient evidence means ‘that a causal
relationship has been established’ between
glyphosate and NHL. BfR’s conclusion is
equivalent to deciding that there is not
sufficient evidence. Legitimate public
health concerns arise when ‘causality is
credible’, that is, when there is limited evi-
dence of carcinogenicity.
EVIDENCE FROM ANIMAL
CARCINOGENICITY STUDIES
EFSA concluded ‘No evidence of carcino-
genicity was confirmed by the majority of
the experts (with the exception of one
minority view) in either rats or mice due
to a lack of statistical significance in pair-
wise comparison tests, lack of consistency
in multiple animal studies and slightly
increased incidences only at dose levels at
or above the limit dose/maximum toler-
ated dose (MTD), lack of preneoplastic
lesions and/or being within historical
control range’. The IARC WG review
found a significant positive trend for renal
tumours in male CD-1 mice,12 a rare
tumour, although no comparisons of any
individual exposure group to the control
group were statistically significant. The
WG also identified a significant positive
trend for hemangiosarcoma in male CD-1
mice,13 again with no individual exposure
group significantly different from con-
trols. Finally, the WG also saw a signifi-
cant increase in the incidence of
pancreatic islet cell adenomas in two
studies in male Sprague-Dawley rats.14–16
In one of these rat studies, thyroid gland
adenomas in females and liver adenomas
in males were also increased. By the IARC
review criteria,1 this constitutes sufficient
evidence in animals.
The IARC WG reached this conclusion
using data that were publicly available in
sufficient detail for independent scientific
evaluation (a requirement of the IARC
Preamble1). On the basis of the BfR
Addendum, it seems there were three add-
itional mouse studies and two additional
rat studies that were unpublished and
available to EFSA. Two of the additional
studies were reported to have a significant
trend for renal tumours, one in CD-1 mice
(Sugimoto. 18-Month Oral Oncogenicity
Study in Mice. Unpublished, designated
ASB2012–11493 in RAR. 1997), and one
in Swiss-Webster mice (Unknown. A
chronic feeding study of glyphosate
(roundup technical) in mice. Unpublished,
designated ABS2012–11491 in RAR.
2001). One of these studies (Sugimoto.
Unpublished, 1997) also reported a signifi-
cant trend for hemangiosarcoma. The
RAR also reported two studies in CD-1
mice showing significant trends for malig-
nant lymphoma (Sugimoto. Unpublished,
1997; Unknown. Glyphosate Technical:
Dietary Carcinogencity Study in
the Mouse. Unpublished, designated
ABS2012–11492 in RAR. 2009).
The RAR dismissed the observed trends
in tumour incidence because there are no
individual treatment groups that are sig-
nificantly different from controls and
because the maximum observed response
is reportedly within the range of the his-
torical control data (Table 5.3–1, p.90).
Care must be taken in using historical
control data to evaluate animal carcino-
genicity data. In virtually all guide-
lines,1 17 18 scientific reports19 and
publications20–23 on this issue, the recom-
mended first choice is the use of concur-
rent controls and trend tests, even in the
EC regulations cited in the RAR18 (see
p.375). Trend tests are more powerful
than pairwise comparisons, particularly
for rare tumours where data are sparse.
Historical control data should be from
studies in the same time frame, for the
same animal strain, preferably from the
same laboratory or the same supplier and
preferably reviewed by the same patholo-
gist.17 18 While the EFSA final peer
review4 mentions the use of historical
control data from the original laboratory,
no specifics are provided and the only
referenced historical control data24 are in
the BfR addendum.5 One of the mouse
studies12 was clearly done before this his-
torical control database was developed,
one study (Sugimoto. Unpublished, 1997)
used Crj:CD-1 mice rather than Crl:CD-1
mice, and one study13 did not specify the
substrain and was reported in 1993 (prob-
ably started prior to 1988). Hence, only a
single study (Unknown. Unpublished,
2009) used the same mouse strain as the
cited historical controls, but was reported
more than 10 years after the historical
control data set was developed.
The RAR dismissed the slightly
increased tumour incidences in the studies
considered because they occurred “only at
dose levels at or above the limit dose/
maximum tolerated dose (MTD)”, and
because there was a lack of preneoplastic
lesions. Exceeding the MTD is demon-
strated by an increase in mortality or
other serious toxicological findings at the
highest dose, not by a slight reduction in
body weight. No serious toxicological
findings were reported at the highest
doses for the mouse studies in the RAR.
While some would argue that these high
doses could cause cellular disruption (eg,
regenerative hyperplasia) leading to
cancer, no evidence of this was reported
in any study. Finally, a lack of preneoplas-
tic lesions for a significant neoplastic
finding is insufficient reason to discard the
finding.
MECHANISTIC INFORMATION
The BfR Addendum dismisses the IARC
WG finding that ‘there is strong evidence
that glyphosate causes genotoxicity’ by
suggesting that unpublished evidence not
seen by the IARC WG was overwhelm-
ingly negative and that, since the reviewed
studies were not done under guideline
principles, they should get less weight. To
maintain transparency, IARC reviews only
publicly available data. The use of confi-
dential data submitted to the BfR makes it
impossible for any scientist not associated
with BfR to review this conclusion.
Further weakening their interpretation,
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the BfR did not include evidence of
chromosomal damage from exposed
humans or human cells that were high-
lighted in Tables 4.1 and 4.2 of the IARC
Monograph 3
The BfR confirms (p.79) that the
studies evaluated by the IARC WG on
oxidative stress were predominantly posi-
tive but does not agree that this is strong
support for an oxidative stress mechan-
ism. They minimise the significance of
these findings predominantly because of a
lack of positive controls in some studies
and because many of the studies used gly-
phosate formulations and not pure gly-
phosate. In contrast, the WG concluded
that (p.77) ‘Strong evidence exists that
glyphosate, AMPA and glyphosate-based
formulations can induce oxidative stress’.
From a scientific perspective, these types
of mechanistic studies play a key role in
distinguishing between the effects of mix-
tures, pure substances and metabolites.
Finally, we strongly disagree that data
from studies published in the peer-
reviewed literature should automatically
receive less weight than guideline studies.
Compliance with guidelines and Good
Laboratory Practice does not guarantee
validity and relevance of the study design,
statistical rigour and attention to sources
of bias.25 26 The majority of research after
the initial marketing approval, including
epidemiology studies, will be conducted
in research laboratories using various
models to address specific issues related to
toxicity, often with no testing guidelines
available. Peer-reviewed and published
findings have great value in understanding
mechanisms of carcinogenicity and should
be given appropriate weight in an evalu-
ation based on study quality, not just on
compliance with guideline rules.
GENERAL COMMENTS
Science moves forward on careful evalua-
tions of data and a rigorous review of
findings, interpretations and conclusions.
An important aspect of this process is
transparency and the ability to question or
debate the findings of others. This ensures
the validity of the results and provides a
strong basis for decisions. Many of the
elements of transparency do not exist for
the RAR.5 For example, citations for
almost all references, even those from the
open scientific literature, have been
redacted. The ability to objectively evalu-
ate the findings of a scientific report
requires a complete list of cited support-
ing evidence. As another example, there
are no authors or contributors listed for
either document, a requirement for publi-
cation in virtually all scientific journals
where financial support, conflicts of inter-
est and affiliations of authors are fully dis-
closed. This is in direct contrast to the
IARC WG evaluation listing all authors,
all publications and public disclosure of
pertinent conflicts of interest prior to the
WG meeting.27
Several guidelines have been devised for
conducting careful evaluation and analysis
of carcinogenicity data, most after con-
sultation with scientists from around the
world. Two of the most widely used
guidelines in Europe are the OECD guid-
ance on the conduct and design of
chronic toxicity and carcinogenicity
studies17 and the European Chemicals
Agency Guidance on Commission
Regulation (EU) No 286/2011;18 both are
cited in the RAR. The methods used for
historical controls and trend analysis are
inconsistent with these guidelines.
Owing to the potential public health
impact of glyphosate, which is an exten-
sively used pesticide, it is essential that all
scientific evidence relating to its possible
carcinogenicity is publicly accessible and
reviewed transparently in accordance with
established scientific criteria.
SUMMARY
The IARC WG concluded that glyphosate
is a ‘probable human carcinogen’, putting
it into IARC category 2A due to sufficient
evidence of carcinogenicity in animals,
limited evidence of carcinogenicity in
humans and strong evidence for two car-
cinogenic mechanisms.
▸ The IARC WG found an association
between NHL and glyphosate based
on the available human evidence.
▸ The IARC WG found significant car-
cinogenic effects in laboratory animals
for rare kidney tumours and heman-
giosarcoma in two mouse studies and
benign tumours in two rat studies.
▸ The IARC WG concluded that there
was strong evidence of genotoxicity
and oxidative stress for glyphosate,
entirely from publicly available
research, including findings of DNA
damage in the peripheral blood of
exposed humans.
The RAR concluded5 (Vol. 1, p.160)
that ‘classification and labelling for car-
cinogenesis is not warranted’ and ‘glypho-
sate is devoid of genotoxic potential’.
▸ EFSA4 classified the human evidence
as ‘very limited’ and then dismissed
any association of glyphosate with
cancer without clear explanation or
justification.
▸ Ignoring established guidelines cited in
their report, EFSA dismissed evidence
of renal tumours in three mouse
studies, hemangiosarcoma in two
mouse studies and malignant lymph-
oma in two mouse studies. Thus, EFSA
incorrectly discarded all findings of
glyphosate-induced cancer in animals
as chance occurrences.
▸ EFSA ignored important laboratory
and human mechanistic evidence of
genotoxicity.
▸ EFSA confirmed that glyphosate
induces oxidative stress but then,
having dismissed all other findings of
possible carcinogenicity, dismissed this
finding on the grounds that oxidative
stress alone is not sufficient for car-
cinogen labelling.
The most appropriate and scientifically
based evaluation of the cancers reported
in humans and laboratory animals as well
as supportive mechanistic data is that gly-
phosate is a probable human carcinogen.
On the basis of this conclusion and in the
absence of evidence to the contrary, it is
reasonable to conclude that glyphosate
formulations should also be considered
likely human carcinogens. The CLP
Criteria18 (Table 3.6.1, p.371) allow for a
similar classification of Category 1B when
there are ‘studies showing limited evi-
dence of carcinogenicity in humans
together with limited evidence of carcino-
genicity in experimental animals’.
In the RAR, almost no weight is given
to studies from the published literature
and there is an over-reliance on non-
publicly available industry-provided
studies using a limited set of assays that
define the minimum data necessary for
the marketing of a pesticide. The IARC
WG evaluation of probably carcinogenic
to humans accurately reflects the results of
published scientific literature on glypho-
sate and, on the face of it, unpublished
studies to which EFSA refers.
Most of the authors of this commentary
previously expressed their concerns to
EFSA and others regarding their review of
glyphosate28 to which EFSA has published
a reply.29 This commentary responds to
the EFSA reply.
The views expressed in this editorial are
the opinion of the authors and do not
imply an endorsement or support for
these opinions by any organisations to
which they are affiliated.
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